Daniel Campbell
About Daniel Campbell
Daniel Campbell is a Product Owner at N-able with a diverse professional background in both the software and pharmaceutical industries. He has held various roles at SolarWinds MSP and GlaxoSmithKline, showcasing expertise in data management, copyright compliance, and customer-centric product development.
Current Role at N-able
Daniel Campbell has been serving as a Product Owner at N-able since 2021. His role involves overseeing product development and ensuring alignment with customer needs. He operates within the Raleigh-Durham-Chapel Hill Area, contributing to the company's focus on delivering effective solutions for its clients.
Previous Experience at SolarWinds MSP
Prior to his current position, Daniel Campbell held multiple roles at SolarWinds MSP. He worked as a Lead Business Analyst for 11 months in 2020, followed by a tenure as Senior Business Analyst from 2018 to 2020, and as a Knowledge Analyst from 2016 to 2018. His experience in these roles emphasized his analytical skills and ability to drive business improvements.
Background in Pharmaceutical Industry
Daniel Campbell has extensive experience in the pharmaceutical sector, having worked at GlaxoSmithKline for 14 years as an Information Scientist. His career began at Glaxo Wellcome, where he served as Document Delivery Specialist II for 6 years. This background provides him with a strong understanding of the industry's complexities and regulatory requirements.
Educational Qualifications
Daniel Campbell earned a Bachelor of Arts (BA) degree from Duke University, where he studied from 1990 to 1994. His education has provided him with a solid foundation in library science, which supports his data management and information resource skills.
Technical Skills and Expertise
Daniel possesses skills in deep log analysis and regular expressions, demonstrating his technical acumen in data handling. He has a comprehensive understanding of copyright compliance, content licensing, and usage rights, which are essential for managing intellectual property. His expertise spans both the software and pharmaceutical industries.